Clearwater has advised the management team at Rosemont Pharmaceuticals (Rosemont), the UK’s leading liquid pharmaceuticals business, on its carve out from US listed company Perrigo, to Inflexion.
Rosemont’s portfolio of over 130 oral liquid medicines includes over 70 licensed products which are sold into the UK as well as the US, Continental Europe and the Middle East. The business benefits from strong R&D and innovation, and has built a track record of successful new product launches.
With substantial experience in successfully executing carve-outs, Inflexion will draw upon its healthcare expertise to establish Rosemont as a standalone business and invest further in innovation and new product development. Inflexion will also support the geographical expansion of the business.
